Blockchain Registration Transaction Record

Lexaria Begins Dosing in Oral Semaglutide Study vs. Wegovy

Lexaria Bioscience launches Human Pilot Study #7 comparing oral DehydraTECH-semaglutide to Wegovy tablets, aiming for safer, effective oral GLP-1 therapy.

This study matters because it tests a potentially safer, oral alternative to injectable GLP-1 drugs like Wegovy, which are widely used for diabetes and weight loss. If Lexaria's DehydraTECH technology succeeds, it could offer patients a more convenient, needle-free option with fewer side effects, disrupting the multibillion-dollar GLP-1 market and expanding access to these medications. For investors, positive results could lead to lucrative partnerships with major pharmaceutical companies.